{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:59:59Z","timestamp":1770307199771,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40263-019-00641-3","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T14:22:32Z","timestamp":1559139752000},"page":"719-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Methylene Blue in the Treatment of Neuropsychiatric Disorders"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9544-3944","authenticated-orcid":false,"given":"Martin","family":"Alda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"641_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/10673220802432350","volume":"16","author":"FR Frankenburg","year":"2008","unstructured":"Frankenburg FR, Baldessarini RJ. Neurosyphilis, malaria, and the discovery of antipsychotic agents. Harv Rev Psychiatry. 2008;16:299\u2013307.","journal-title":"Harv Rev Psychiatry."},{"key":"641_CR2","doi-asserted-by":"publisher","DOI":"10.4159\/9780674038455","volume-title":"The creation of psychopharmacology","author":"D Healy","year":"2002","unstructured":"Healy D. The creation of psychopharmacology. London: Harvard University Press; 2002."},{"key":"641_CR3","unstructured":"WHO. The selection and use of essential medicines. Report of the WHO Expert Committee, 2015 (including the 19th WHO Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2015: WHO Technical Report Series, no. 994. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/189763\/1\/9789241209946_eng.pdf\n                    \n                  . Accessed 18 May 2019."},{"key":"641_CR4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s11011-017-0081-6","volume":"32","author":"A Delport","year":"2017","unstructured":"Delport A, Harvey BH, Petzer A, Petzer JP. Methylene blue and its analogues as antidepressant compounds. Metab Brain Dis. 2017;32:1357\u201382.","journal-title":"Metab Brain Dis."},{"key":"641_CR5","unstructured":"US FDA. Drug safety communication: updated information about the drug interaction between methylene blue (methylthioninium chloride) and serotonergic psychiatric medications. \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm276119.htm\n                    \n                  . Accessed 18 May 2019."},{"key":"641_CR6","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1021\/acschemneuro.8b00042","volume":"9","author":"A Delport","year":"2018","unstructured":"Delport A, Harvey BH, Petzer A, Petzer JP. Methylene blue analogues with marginal monoamine oxidase inhibition retain antidepressant-like activity. ACS Chem Neurosci. 2018;9:2917\u201328.","journal-title":"ACS Chem Neurosci."},{"key":"641_CR7","first-page":"74","volume":"6","author":"K Rysanek","year":"1964","unstructured":"Rysanek K, Vitek V, Vojtechovsky M. Interpretation of the psychostimulating effect of methylene blue. Act Nerv Super (Praha). 1964;6:74\u20136.","journal-title":"Act Nerv Super (Praha)."},{"key":"641_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0028-3908(03)00278-8","volume":"45","author":"CD Munhoz","year":"2003","unstructured":"Munhoz CD, Glezer I, Kawamoto EM, Araujo AP, Lepscha LB, Planeta CS, et al. Changes in sodium, potassium-ATPase induced by repeated fencamfamine: the roles of cyclic AMP-dependent protein kinase and the nitric oxide-cyclic GMP pathway. Neuropharmacology. 2003;45:1151\u20139.","journal-title":"Neuropharmacology."},{"key":"641_CR9","first-page":"191","volume":"54","author":"J Beltowski","year":"2003","unstructured":"Beltowski J, Marciniak A, Wojcicka G, Gorny D. Nitric oxide decreases renal medullary Na\u2009+\u2009, K\u2009+\u2009-ATPase activity through cyclic GMP-protein kinase G dependent mechanism. J Physiol Pharmacol. 2003;54:191\u2013210.","journal-title":"J Physiol Pharmacol."},{"key":"641_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0166-4328(02)00084-0","volume":"134","author":"IL Heiberg","year":"2002","unstructured":"Heiberg IL, Wegener G, Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res. 2002;134:479\u201384.","journal-title":"Behav Brain Res."},{"key":"641_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/nyas.13870","volume":"1431","author":"S Bhurtel","year":"2018","unstructured":"Bhurtel S, Katila N, Neupane S, Srivastav S, Park PH, Choi DY. Methylene blue protects dopaminergic neurons against MPTP-induced neurotoxicity by upregulating brain-derived neurotrophic factor. Ann N Y Acad Sci. 2018;1431:58\u201371.","journal-title":"Ann N Y Acad Sci."},{"key":"641_CR12","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1002\/jcp.27339","volume":"234","author":"C Chen","year":"2019","unstructured":"Chen C, Zhou F, Zeng L, Jiang Z, Hu Z. Methylene blue offers neuroprotection after intracerebral hemorrhage in rats through the PI3\u00a0K\/Akt\/GSK3beta signaling pathway. J Cell Physiol. 2019;234:5304\u201318.","journal-title":"J Cell Physiol."},{"key":"641_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pneurobio.2011.10.007","volume":"96","author":"JC Rojas","year":"2012","unstructured":"Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96:32\u201345.","journal-title":"Prog Neurobiol."},{"key":"641_CR14","doi-asserted-by":"publisher","first-page":"16504","DOI":"10.1074\/jbc.M110.208447","volume":"286","author":"Y Wen","year":"2011","unstructured":"Wen Y, Li W, Poteet EC, Xie L, Tan C, Yan LJ, et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem. 2011;286:16504\u201315.","journal-title":"J Biol Chem."},{"key":"641_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/FPC.0b013e32836498f4","volume":"23","author":"EM McDonagh","year":"2013","unstructured":"McDonagh EM, Bautista JM, Youngster I, Altman RB, Klein TE. PharmGKB summary: methylene blue pathway. Pharmacogenet Genomics. 2013;23:498\u2013508.","journal-title":"Pharmacogenet Genomics."},{"key":"641_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fncel.2017.00391","volume":"11","author":"ZH Lin","year":"2017","unstructured":"Lin ZH, Wang SY, Chen LL, Zhuang JY, Ke QF, Xiao DR, et al. Methylene blue mitigates acute neuroinflammation after spinal cord injury through inhibiting NLRP3 inflammasome activation in microglia. Front Cell Neurosci. 2017;11:391.","journal-title":"Front Cell Neurosci."},{"key":"641_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbi.2017.04.020","volume":"65","author":"H Xu","year":"2017","unstructured":"Xu H, Li J, Wang Z, Feng M, Shen Y, Cao S, et al. Methylene blue attenuates neuroinflammation after subarachnoid hemorrhage in rats through the Akt\/GSK-3beta\/MEF2D signaling pathway. Brain Behav Immun. 2017;65:125\u201339.","journal-title":"Brain Behav Immun."},{"key":"641_CR18","doi-asserted-by":"publisher","first-page":"12409","DOI":"10.1038\/s41598-017-12635-6","volume":"7","author":"H Ahn","year":"2017","unstructured":"Ahn H, Kang SG, Yoon SI, Ko HJ, Kim PH, Hong EJ, et al. Methylene blue inhibits NLRP3, NLRC4, AIM2, and non-canonical inflammasome activation. Sci Rep. 2017;7:12409.","journal-title":"Sci Rep."},{"key":"641_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.redox.2015.01.008","volume":"4","author":"A Abderrazak","year":"2015","unstructured":"Abderrazak A, Syrovets T, Couchie D, El HK, Friguet B, Simmet T, et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 2015;4:296\u2013307.","journal-title":"Redox Biol."},{"key":"641_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/0006-3223(89)90128-5","volume":"26","author":"JP Moody","year":"1989","unstructured":"Moody JP, Allan SM, Smith AH, Naylor GJ. Methylene blue excretion in depression. Biol Psychiatry. 1989;26:850\u20132.","journal-title":"Biol Psychiatry."},{"key":"641_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lfs.2014.10.005","volume":"117","author":"A Delport","year":"2014","unstructured":"Delport A, Harvey BH, Petzer A, Petzer JP. Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties. Life Sci. 2014;117:56\u201366.","journal-title":"Life Sci."},{"key":"641_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s002280000124","volume":"56","author":"C Peter","year":"2000","unstructured":"Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000;56:247\u201350.","journal-title":"Eur J Clin Pharmacol."},{"key":"641_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1006\/phrs.1997.0245","volume":"36","author":"L Eroglu","year":"1997","unstructured":"Eroglu L, Caglayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res. 1997;36:381\u20135.","journal-title":"Pharmacol Res."},{"key":"641_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/0006-3223(87)90194-6","volume":"22","author":"GJ Naylor","year":"1987","unstructured":"Naylor GJ, Smith AH, Connelly P. A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry. 1987;22:657\u20139.","journal-title":"Biol Psychiatry."},{"key":"641_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/0006-3223(86)90265-9","volume":"21","author":"GJ Naylor","year":"1986","unstructured":"Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry. 1986;21:915\u201320.","journal-title":"Biol Psychiatry."},{"key":"641_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1192\/bjp.bp.115.173930","volume":"210","author":"M Alda","year":"2017","unstructured":"Alda M, McKinnon M, Blagdon R, Garnham J, MacLellan S, O\u2019Donovan C, et al. Methylene blue for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatry. 2017;210:54\u201360.","journal-title":"Br J Psychiatry."},{"key":"641_CR27","unstructured":"US FDA. Drug safety communication: serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm263190.htm\n                    \n                  . Accessed 18 May 2019."},{"key":"641_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.psym.2018.06.012","volume":"59","author":"ZD Zuschlag","year":"2018","unstructured":"Zuschlag ZD, Warren MW, Schultz K. Serotonin toxicity and urinary analgesics: a case report and systematic literature review of methylene blue-induced serotonin syndrome. Psychosomatics. 2018;59:539\u201346.","journal-title":"Psychosomatics."},{"key":"641_CR29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(81)90630-9","volume":"2","author":"GJ Naylor","year":"1981","unstructured":"Naylor GJ, Dick DA, Johnston BB, Hopwood SE, Dick EG, Smith AH, et al. Possible explanation for therapeutic action of lithium, and a possible substitute (methylene-blue). Lancet. 1981;2:1175\u20136.","journal-title":"Lancet."},{"key":"641_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0165-0327(83)90008-3","volume":"5","author":"SL Narsapur","year":"1983","unstructured":"Narsapur SL, Naylor GJ. Methylene blue: a possible treatment for manic depressive psychosis. J Affect Disord. 1983;5:155\u201361.","journal-title":"J Affect Disord."},{"key":"641_CR31","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/0006-3223(88)90229-6","volume":"24","author":"GJ Naylor","year":"1988","unstructured":"Naylor GJ, Smith AH, Connelly P. Methylene blue in mania. Biol Psychiatry. 1988;24:941\u20132.","journal-title":"Biol Psychiatry."},{"key":"641_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/00002826-199708000-00008","volume":"20","author":"SI Deutsch","year":"1997","unstructured":"Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol. 1997;20:357\u201363.","journal-title":"Clin Neuropharmacol."},{"key":"641_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1742-7843.2004.pto940203.x","volume":"94","author":"D Klamer","year":"2004","unstructured":"Klamer D, Engel JA, Svensson L. Phencyclidine-induced behaviour in mice prevented by methylene blue. Basic Clin Pharmacol Toxicol. 2004;94:65\u201372.","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"641_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamapsychiatry.2013.1292","volume":"70","author":"JE Hallak","year":"2013","unstructured":"Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013;70:668\u201376.","journal-title":"JAMA Psychiatry."},{"key":"641_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1176\/appi.ajp.2014.13101407","volume":"171","author":"MJ Telch","year":"2014","unstructured":"Telch MJ, Bruchey AK, Rosenfield D, Cobb AR, Smits J, Pahl S, et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry. 2014;171:1091\u20138.","journal-title":"Am J Psychiatry."},{"key":"641_CR36","doi-asserted-by":"publisher","first-page":"e782","DOI":"10.4088\/JCP.16m10936","volume":"78","author":"LA Zoellner","year":"2017","unstructured":"Zoellner LA, Telch M, Foa EB, Farach FJ, McLean CP, Gallop R, et al. Enhancing extinction learning in posttraumatic stress disorder with brief daily imaginal exposure and methylene blue: a randomized controlled trial. J Clin Psychiatry. 2017;78:e782\u20139.","journal-title":"J Clin Psychiatry."},{"key":"641_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/neu.2014.3514","volume":"32","author":"AM Fenn","year":"2015","unstructured":"Fenn AM, Skendelas JP, Moussa DN, Muccigrosso MM, Popovich PG, Lifshitz J, et al. Methylene blue attenuates traumatic brain injury-associated neuroinflammation and acute depressive-like behavior in mice. J Neurotrauma. 2015;32:127\u201338.","journal-title":"J Neurotrauma."},{"key":"641_CR38","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1007\/s12035-015-9455-0","volume":"53","author":"Q Lu","year":"2016","unstructured":"Lu Q, Tucker D, Dong Y, Zhao N, Zhang Q. Neuroprotective and functional improvement effects of methylene blue in global cerebral ischemia. Mol Neurobiol. 2016;53:5344\u201355.","journal-title":"Mol Neurobiol."},{"key":"641_CR39","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1007\/s12035-017-0712-2","volume":"55","author":"D Tucker","year":"2018","unstructured":"Tucker D, Lu Y, Zhang Q. From mitochondrial function to neuroprotection: an emerging role for methylene blue. Mol Neurobiol. 2018;55:5137\u201353.","journal-title":"Mol Neurobiol."},{"key":"641_CR40","doi-asserted-by":"crossref","first-page":"232470961878676","DOI":"10.1177\/2324709618786769","volume":"6","author":"A Vakiti","year":"2018","unstructured":"Vakiti A, Pilla R, Alhaj MM, Joseph JJ, Shenoy AG. Ifosfamide-induced metabolic encephalopathy in 2 patients with cutaneous T-cell lymphoma successfully treated with methylene blue. J Investig Med High Impact Case Rep. 2018;6:2324709618786769.","journal-title":"J Investig Med High Impact Case Rep."},{"key":"641_CR41","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/FBP.0000000000000133","volume":"26","author":"V Melis","year":"2015","unstructured":"Melis V, Magbagbeolu M, Rickard JE, Horsley D, Davidson K, Harrington KA, et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol. 2015;26:353\u201368.","journal-title":"Behav Pharmacol."},{"key":"641_CR42","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1097\/CCM.0b013e3181f26b0c","volume":"38","author":"A Miclescu","year":"2010","unstructured":"Miclescu A, Sharma HS, Martijn C, Wiklund L. Methylene blue protects the cortical blood-brain barrier against ischemia\/reperfusion-induced disruptions. Crit Care Med. 2010;38:2199\u2013206.","journal-title":"Crit Care Med."},{"key":"641_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/(SICI)1097-4652(199604)167:1<89::AID-JCP10>3.0.CO;2-K","volume":"167","author":"RD Hurst","year":"1996","unstructured":"Hurst RD, Fritz IB. Nitric oxide-induced perturbations in a cell culture model of the blood-brain barrier. J Cell Physiol. 1996;167:89\u201394.","journal-title":"J Cell Physiol."},{"key":"641_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/JAD-142874","volume":"44","author":"CM Wischik","year":"2015","unstructured":"Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease. J Alzheimers Dis. 2015;44:705\u201320.","journal-title":"J Alzheimers Dis."},{"key":"641_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1124\/jpet.114.219352","volume":"352","author":"TC Baddeley","year":"2015","unstructured":"Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease. J Pharmacol Exp Ther. 2015;352:110\u20138.","journal-title":"J Pharmacol Exp Ther."},{"key":"641_CR46","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.biopsych.2017.11.018","volume":"83","author":"L Pei","year":"2018","unstructured":"Pei L, Wallace DC. Mitochondrial etiology of neuropsychiatric disorders. Biol Psychiatry. 2018;83:722\u201330.","journal-title":"Biol Psychiatry."},{"key":"641_CR47","first-page":"1277","volume":"56","author":"FJ McMahon","year":"1995","unstructured":"McMahon FJ, Stine OC, Meyers DA, Simpson SG, DePaulo JR. Patterns of maternal transmission in bipolar affective disorder. Am J Hum Genet. 1995;56:1277\u201386.","journal-title":"Am J Hum Genet."},{"key":"641_CR48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/sj.mp.4001824","volume":"11","author":"T Kasahara","year":"2006","unstructured":"Kasahara T, Kubota M, Miyauchi T, Noda Y, Mouri A, Nabeshima T, et al. Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. Mol Psychiatry. 2006;11:577\u201393.","journal-title":"Mol Psychiatry."},{"key":"641_CR49","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/archpsyc.61.3.300","volume":"61","author":"C Konradi","year":"2004","unstructured":"Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300\u20138.","journal-title":"Arch Gen Psychiatry."},{"key":"641_CR50","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/archgenpsychiatry.2010.22","volume":"67","author":"AC Andreazza","year":"2010","unstructured":"Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry. 2010;67:360\u20138.","journal-title":"Arch Gen Psychiatry."},{"key":"641_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ijdevneu.2010.08.007","volume":"29","author":"HB Clay","year":"2011","unstructured":"Clay HB, Sillivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci. 2011;29:311\u201324.","journal-title":"Int J Dev Neurosci."},{"key":"641_CR52","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2018.7606","author":"Y Kim","year":"2019","unstructured":"Kim Y, Vadodaria KC, Lenkei Z, Kato T, Gage FH, Marchetto MC, et al. Mitochondria, metabolism, and redox mechanisms in psychiatric disorders. Antioxid Redox Signal. 2019. \n                    https:\/\/doi.org\/10.1089\/ars.2018.7606\n                    \n                  .","journal-title":"Antioxid Redox Signal."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00641-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00641-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00641-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T23:33:19Z","timestamp":1590622399000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00641-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00641-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"29 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Some of the results reported here and published previously were obtained with support from the Stanley Medical Research Institute. No other funding was used for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Martin Alda has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}